Patent US5160737A successfully refreshed from Google Patents.
US5160737A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Liquid polymer composition, and method of use
Assignee: Dexcel Pharma Technologies Ltd
•
Filing: 1990-03-28
•
Granted: 1992-11-03
•
Expires: 2010-03-28
Abstract
Abstract The invention relates to a liquid methacrylic acid copolymer composition that contains a release adjusting agent and a pharmacological agent. The composition forms a solid film upon drying, and is capable of accomplishing the sustained release of the pharmacological agent such as to permit its use in the treatment or prevention of dental or dermatological conditions.
Inventors
- 👤 Michael Friedman
- 👤 Amnon Sintov
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 12:51
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0053; A61K9/006; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/415; A61K31/70; A61K6/00; A61K6/50; A61K6/52; A61K6/60; A61K6/65; A61K6/69; A61K9/0063; A61P; A61P1/00; A61P1/02; A61P31/00; A61P31/04; A61P31/10
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
224 words
A sustained-released liquid polymer composition which consists essentially of: (a) one or more sustained release acrylic polymers; (b) a pharmacological agent; (c) a release adjusting agent selected from the group consisting of a cross-linking agent, a polysaccharide, a lipid, a protein, a sodium citrate, sodium docusate, an amino acid and sodium polyphosphate; and (d) a pharmaceutically acceptable vehicle selected from the group consisting of water; ethyl alcohol; and ethyl alcohol and water, wherein said sustained release acrylic polymers are selected from the group consisting of: (1) a methacrylic acid type A copolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:1; (2) a methacrylic acid type B compolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:2, (3) a dimethylaminoethylacrylate/ethylmethacrylate copolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:20; and (4) an ethyl methacrylate/chlorotrimethylammoniumethyl methacrylate copolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40.
Claim 2
Dependent Claim
224 words
A sustained-released liquid polymer composition which consists essentially of: (a) one or more sustained release acrylic polymers; (b) a pharmacological agent; (c) a release adjusting agent selected from the group consisting of a cross-linking agent, a polysaccharide, a lipid, a protein, a sodium citrate, sodium docusate, an amino acid and sodium polyphosphate; and (d) a pharmaceutically acceptable vehicle selected from the group consisting of water; ethyl alcohol; and ethyl alcohol and water, wherein said sustained release acrylic polymers are selected from the group consisting of: (1) a methacrylic acid type A copolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:1; (2) a methacrylic acid type B compolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:2, (3) a dimethylaminoethylacrylate/ethylmethacrylate copolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:20; and (4) an ethyl methacrylate/chlorotrimethylammoniumethyl methacrylate copolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40.
Claim 3
Dependent Claim
25 words
The liquid polymer composition of claim 1, wherein said amino acid is selected from the group consisting of: arginine, lysine, aspartic acid, and glutaric acid.
Claim 4
Dependent Claim
32 words
The liquid polymer composition of claim 1, wherein said pharmacological agent is selected from the group consisting of: an antibiotic, an antiseptic, an anti-fungal agent, an anti-viral agent, and a hypersensitivity agent.
Claim 5
Dependent Claim
17 words
The liquid polymer composition of claim 1, wherein said pharmacological agent is a bacteriocidal quaternary ammonium salt.
Claim 6
Dependent Claim
25 words
The liquid polymer composition of claim 4 wherein said bacteriocidal quaternary ammonium salt is selected from the group consisting of cetylpyridinium chloride and benzalkonium chloride.
Claim 7
Dependent Claim
16 words
The liquid polymer composition of claim 5, wherein said bacteriocidal quaternary ammonium salt is cetylpyridinium chloride.
Claim 8
Dependent Claim
16 words
The liquid polymer composition of claim 5, wherein said bacteriocidal quaternary ammonium salt is benzalkonium chloride.
Claim 9
Dependent Claim
15 words
The liquid polymer composition of claim 3, wherein said pharmacological agent is a hypersensitivity agent.
Claim 10
Dependent Claim
29 words
The liquid polymer composition of claim 8, wherein said hypersensitivity agent is selected from the group consisting of a strontium salt, a potassium salt, a fluoride and an oxylate.
Claim 11
Dependent Claim
23 words
The liquid polymer composition of claim 9, wherein said strontium salt is selected from the group consisting of strontium chloride and strontium citrate.
Claim 12
Dependent Claim
26 words
The liquid polymer composition of claim 9, wherein said potassium salt is selected from the group consisting of potassium chloride, potassium hydrogen tartrate and potassium nitrate.
Claim 13
Dependent Claim
13 words
The liquid polymer composition of claim 9, wherein said fluoride is stannous fluoride.
Claim 14
Dependent Claim
14 words
The liquid polymer composition of claim 9, wherein said oxylate is potassium hydrogen oxylate.
Claim 15
Dependent Claim
226 words
A sustained-released liquid polymer composition which consists essentially of: (a) one or more sustained release acrylic polymers; (b) a pharmacological agent; (c) a release adjusting agent selected from the group consisting of a cross-linking agent, a polysaccharide, a lipid, a protein, a sodium citrate, sodium docusate, an amino acid and sodium polyphosphate; (d) a pharmaceutically acceptable vehicle selected from the group consisting of water; ethyl alcohol; and ethyl alcohol and water; and (e) a plasticizer; wherein said sustained release acrylic polymers are selected from the group consisting of: (1) a methacrylic acid type A copolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:1; (2) a methacrylic acid type B copolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:2; (3) a dimethylaminoethylacrylate/ethylmethacrylatecopolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:20; and (4) an ethyl methacrylate/chlorotrimethylammoniumethyl methacrylate copolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40.
Claim 16
Dependent Claim
226 words
A sustained-released liquid polymer composition which consists essentially of: (a) one or more sustained release acrylic polymers; (b) a pharmacological agent; (c) a release adjusting agent selected from the group consisting of a cross-linking agent, a polysaccharide, a lipid, a protein, a sodium citrate, sodium docusate, an amino acid and sodium polyphosphate; (d) a pharmaceutically acceptable vehicle selected from the group consisting of water; ethyl alcohol; and ethyl alcohol and water; and (e) a plasticizer; wherein said sustained release acrylic polymers are selected from the group consisting of: (1) a methacrylic acid type A copolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:1; (2) a methacrylic acid type B copolymer, an anionic copolymer based on methacrylic acid and methylmethacrylate wherein the ratio of free carboxyl groups to the ester groups is approximately 1:2; (3) a dimethylaminoethylacrylate/ethylmethacrylatecopolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:20; and (4) an ethyl methacrylate/chlorotrimethylammoniumethyl methacrylate copolymer, a copolymer based on acrylic and methacrylic acid esters with a low content of quaternary ammonium groups wherein the molar ratio of the ammonium groups to the remaining neutral (meth)acrylic acid esters is 1:40.
Claim 17
Dependent Claim
22 words
The liquid polymer composition of claim 14, wherein said plasticizer is selected from the group consisting of: polyethylene glycol and dibutyl phthalate.
Claim 18
Dependent Claim
27 words
The liquid polymer composition of claim 1, wherein said cross-linking agent is selected from the group consisting of glutaraldehyde, citric acid, lysine, aspartic acid, and glutaric acid.
Claim 19
Dependent Claim
12 words
The liquid polymer composition of claim 1, wherein said polysaccharide is dextran.
Claim 20
Dependent Claim
13 words
The liquid polymer composition of claim 1, wherein said lipid is sodium docusate.
References Cited (Backward Citations)
US2984639A
Cited
GB1324798A
Cited
GB1294173A
Cited
US3846542A
Cited
GB1431211A
Cited
US3925895A
Cited
US3956480A
Cited
US4011309A
Cited
US4554156A
Cited
US4539199A
Cited
GB2128087A
Cited
EP0140766A2
Cited
US4751072A
Cited
US4645662A
Cited
US4963347A
Cited
EP0184389A2
Cited
US4701320A
Cited
US4683134A
Cited
US4775525A
Cited
AU6670786A
Cited
US4876092A
Cited
US4911922A
Cited
JPS6360924A
Cited
AU7955787A
Cited
EP0265228A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-11-03 | 1996-05-04 | 1996-11-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-11-03 | 2000-05-04 | 2000-11-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-11-03 | 2004-05-04 | 2004-11-03 | $7700.00 | Window Closed / Lapsed |